3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Gastrointestinal
1
Conditions
Melanoma
114
Carcinoma, Non-Small-Cell Lung
34
Neoplasms
26
Neoplasm Metastasis
19
Prostatic Neoplasms
18
Uveal Melanoma
16
Carcinoma, Renal Cell
16
Lung Neoplasms
14
Pancreatic Neoplasms
13
Diabetes Mellitus, Insulin-Dependent, 12
12
Small Cell Lung Carcinoma
11
Colorectal Neoplasms
10
Carcinoma, Hepatocellular
9
Uterine Cervical Neoplasms
8
Squamous Cell Carcinoma of Head and Neck
8
Breast Neoplasms
8
Sarcoma
7
Carcinoma, Transitional Cell
7
Brain Neoplasms
7
Stomach Neoplasms
6
Mesothelioma
6
Kidney Neoplasms
6
Head and Neck Neoplasms
6
Advanced Cancer
6
Urinary Bladder Neoplasms
5
Recurrence
5
Ovarian Neoplasms
5
Lymphoma, Non-Hodgkin
5
Lymphoma
5
Leukemia, Myeloid, Acute
5
Interventions
relatlimab
1
daratumumab
1
cobimetinib
1
Nivolumab
1
Ipilimumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Microsatellite Unstable Colorectal Cancer
×
Ipilimumab
×
Clear all
NCT02060188
2025-11-06
CheckMate142
Bristol-Myers Squibb
Phase 2
Completed
385 enrolled
17 charts
2 FDA